Personalized medicine refers to the utilization of technologies at the molecular level to understand disease processes and improve health outcomes. In rheumatoid arthritis (RA) some factors associated with disease outcome have been identified. These factors have not yet been integrated into a clinically useful tool to predict disease outcome in individual patients. Developments in pharmacogenomics are moving the field forward quite rapidly. Genetic variants, which may have a role in drug metabolism mediating either drug response or toxicity, have been identified for both traditional disease modifying antirheumatic drugs and biologic agents. Choosing a medication based on a patient’s characteristics (sociodemographic, clinical, genetic) will result in better utilization of resources and better clinical outcomes. The ethical, political, and legal implications of personalized medicine need to be considered as well.
Berkun, Y., Levartovsky, D., Rubinow, A., Orbach, H., Aamar, S., Grenader, T. et al. (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis63: 1227-1231.
2.
Black, A.J., McLeod, H.L., Capell, H.A., Powrie, R.H., Matowe, L.K., Pritchard, S.C. et al. (1998) Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med129: 716-718.
3.
Blum, M., Demierre, A., Grant, D.M., Heim, M. and Meyer, U.A. ( 1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA88: 5237-5241.
4.
Bridges Jr, S.L. ( 2004) Genetic markers of treatment response in rheumatoid arthritis . Arthritis Rheum50: 1019-1022.
5.
Bridges Jr, S.L. ( 2007) Personalized medicine in rheumatoid arthritis: hopes and challenges. Bull NYU Hosp Jt Dis65: 174-177.
6.
Buch, M.H., Reece, R.J., Quinn, M.A., English, A., Cunnane, G., Henshaw, K. et al. (2008) The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology47: 1469-1475.
7.
Buch, M.H., Boyle, D.L., Rosengren, S., Saleem, B., Reece, R.J., Rhodes, L.A. et al. (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI pilot study. Ann Rheum Dis68: 1220-1227.
8.
Canete, J.D., Suarez, B., Hernandez, M.V., Sanmarti, R., Rego, I., Celis, R. et al. (2009) Influence of variants of Fc{gamma}receptors IIA and IIIA on the ACR and EULAR responses to anti-TNF{alpha} therapy in rheumatoid arthritis . Ann Rheum Dis68: 1547-1552.
9.
Catrina, A.I., Lampa, J., Ernestam, S., af Klint, E., Bratt, J., Klareskog, L. et al. (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology41: 484-489.
10.
Coenen, M.J., Toonen, E.J., Scheffer, H., Radstake, T.R., Barrera, P. and Franke, B. ( 2007) Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics8: 761-773.
11.
Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C. et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum54: 2793-2806.
12.
Criswell, L.A., Lum, R.F., Turner, K.N., Woehl, B., Zhu, Y., Wang, J. et al. (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum50: 2750-2756.
13.
Cuchacovich, M., Soto, L., Edwardes, M., Gutierrez, M., Llanos, C., Pacheco, D. et al. (2006) Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol35: 435-440.
14.
Dass, S., Rawstron, A.C., Vital, E.M., Henshaw, K., McGonagle, D. and Emery, P. ( 2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum58: 2993-2999.
15.
Dervieux, T., Furst, D., Lein, D.O., Capps, R., Smith, K., Caldwell, J. et al. (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis64: 1180-1185.
16.
Dervieux, T., Greenstein, N. and Kremer, J. ( 2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum54: 3095-3103.
17.
Drozdzik, M., Rudas, T., Pawlik, A., Kurzawski, M., Czerny, B., Gornik, W. et al. (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs . Eur J Clin Pharmacol62: 933-937.
18.
Emery, P., McInnes, I.B., van Vollenhoven, R. and Kraan, M.C.(2008) Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology47: 392-398.
19.
Fabre, S., Dupuy, A.M., Dossat, N., Guisset, C., Cohen, J.D., Cristol, J.P. et al. (2008) Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol153: 188-195.
20.
Fonseca, J.E., Carvalho, T., Cruz, M., Nero, P., Sobral, M., Mourao, A.F. et al. (2005) Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis64: 793-794.
21.
Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G. et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet10: 111-113.
22.
Hickman, D. and Sim, E. ( 1991) N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol42: 1007-1014.
23.
Hider, S.L., Bruce, I.N. and Thomson, W. ( 2007) The pharmacogenetics of methotrexate. Rheumatology46: 1520-1524.
24.
Hughes, L.B., Beasley, T.M., Patel, H., Tiwari, H.K., Morgan, S.L., Baggott, J.E. et al. (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis . Ann Rheum Dis65: 1213-1218.
Kang, C.P., Lee, K.W., Yoo, D.H., Kang, C. and Bae, S.C. ( 2005) The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology44: 547-552.
27.
Kastbom, A., Bratt, J., Ernestam, S., Lampa, J., Padyukov, L., Soderkvist, P. et al. (2007) Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum56: 448-452.
28.
Kavanaugh, A., Rosengren, S., Lee, S.J., Hammaker, D., Firestein, G.S., Kalunian, K. et al. (2008) Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results . Ann Rheum Dis67: 402-408.
29.
Koczan, D., Drynda, S., Hecker, M., Drynda, A., Guthke, R., Kekow, J. et al. (2008) Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept . Arthritis Res Ther10: R50.
30.
Kumagai, K., Hiyama, K., Oyama, T., Maeda, H. and Kohno, N. ( 2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med11: 593-600.
31.
Kurzawski, M., Pawlik, A., Safranow, K., Herczynska, M. and Drozdzik, M. ( 2007) 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics8: 1551-1559.
32.
Leandro, M.J., Cambridge, G., Ehrenstein, M.R. and Edwards, J.C. ( 2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum54: 613-620.
33.
Lequerre, T., Gauthier-Jauneau, A.C., Bansard, C., Derambure, C., Hiron, M., Vittecoq, O. et al. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther8: R105.
34.
Lindberg, J., af Klint, E., Catrina, A.I., Nilsson, P., Klareskog, L., Ulfgren, A.K. et al. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther8: R179.
35.
Lipsky, P.E., van der Heijde, D.M.F.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R. et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med343: 1594-1602.
36.
Liu, C., Batliwalla, F., Li, W., Lee, A., Roubenoff, R., Beckman, E. et al. (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med14: 575-581.
37.
Marotte, H., Pallot-Prades, B., Grange, L., Tebib, J., Gaudin, P., Alexandre, C. et al. (2006) The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis65: 342-347.
38.
Martinez, A., Salido, M., Bonilla, G., Pascual-Salcedo, D., Fernandez-Arquero, M., de Miguel, S. et al. (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum50: 1077-1082.
39.
Maxwell, J.R., Potter, C., Hyrich, K.L., Barton, A., Worthington, J., Isaacs, J.D. et al. (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet17: 3532-3538.
40.
Miceli-Richard, C., Comets, E., Verstuyft, C., Tamouza, R., Loiseau, P., Ravaud, P. et al. (2008) A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis67: 478-484.
41.
Padyukov, L., Lampa, J., Heimburger, M., Ernestam, S., Cederholm, T., Lundkvist, I. et al. (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis62: 526-529.
42.
Pawlik, A., Herczynska, M., Kurzawski, M., Safranow, K., Dziedziejko, V. and Drozdzik, M.(2009) The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics10: 303-309.
43.
Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I. and Gawronska-Szklarz, B. ( 2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther42: 496-503.
44.
Pinto, J.A., Rego, I., Rodriguez-Gomez, M., Canete, J.D., Fernandez-Lopez, C., Freire, M. et al. (2008) Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol35: 177-178.
45.
Pullar, T., Hunter, J.A. and Capell, H.A. ( 1985) Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis44: 831-837.
46.
Ranganathan, P., Culverhouse, R., Marsh, S., Mody, A., Scott-Horton, T.J., Brasington, R. et al. (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol35: 572-579.
47.
Roll, P., Dorner, T. and Tony, H.P. ( 2008) Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment . Arthritis Rheum58: 1566-1575.
48.
Rooryck, C., Barnetche, T., Richez, C., Laleye, A., Arveiler, B. and Schaeverbeke, T. ( 2008) Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol26: 340-342.
49.
Roux-Lombard, P., Eberhardt, K., Saxne, T., Dayer, J.M. and Wollheim, F.A. ( 2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology40: 544-551.
50.
Schwahn, B. and Rozen, R. ( 2001) Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics1: 189-201.
51.
Seeringer, A. and Kirchheiner, J. ( 2008) Pharmacogenetics-guided dose modifications of antidepressants . Clin Lab Med28: 619-626.
52.
Seitz, M., Wirthmuller, U., Moller, B. and Villiger, P.M. ( 2007) The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology46: 93-96.
53.
Sekiguchi, N., Kawauchi, S., Furuya, T., Inaba, N., Matsuda, K., Ando, S. et al. (2008) Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology47: 780-788.
54.
Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A. et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet353: 259-266.
55.
Smolen, J.S., van der Heijde, D.M., St Clair, E.W., Emery, P., Bathon, J.M., Keystone, E. et al. (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum54: 702-710.
56.
Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G. et al. (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med159: 2542-2550.
57.
Takatori, R., Takahashi, K.A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T. et al. (2006) ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol24: 546-554.
58.
Tanaka, E., Taniguchi, A., Urano, W., Nakajima, H., Matsuda, Y., Kitamura, Y. et al. (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol29: 2492-2499.
59.
Toonen, E.J., Coenen, M.J., Kievit, W., Fransen, J., Eijsbouts, A.M., Scheffer, H. et al. (2008) The tumour necrosis factor receptor superfamily member 1b
60.
676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis67: 1174-1177.
61.
Tutuncu, Z., Kavanaugh, A., Zvaifler, N., Corr, M., Deutsch, R. and Boyle, D. ( 2005) Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum52: 2693-2696.
62.
Ulrich, C.M., Robien, K. and Sparks, R. ( 2002) Pharmacogenetics and folate metabolism - a promising direction . Pharmacogenomics3: 299-313.
63.
Urano, W., Taniguchi, A., Yamanaka, H., Tanaka, E., Nakajima, H., Matsuda, Y. et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics12: 183-190.
64.
van Ede, A.E., Laan, R.F., Blom, H.J., Huizinga, T.W., Haagsma, C.J., Giesendo, B.A. et al. (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum44: 2525-2530.
65.
Vogel, F. ( 1959) Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilkd12: 52.
66.
Voskuyl, A.E. and Dijkmans, B.A. ( 2006) Remission and radiographic progression in rheumatoid arthritis . Clin Exp Rheumatol24: S-40.
67.
Wessels, J.A., Kooloos, W.M., De Jonge, R., Vries-Bouwstra, J.K., Allaart, C.F., Linssen, A. et al. (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum54: 2830-2839.
68.
Zhou, S.F., Di, Y.M., Chan, E., Du, Y.M., Chow, V.D., Xue, C.C. et al. (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab9: 738-784.
